サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1787264

局所ドラッグデリバリーの世界市場：製品別、用途別、エンドユーザー別、地域別 - 予測（～2030年）

Topical Drug Delivery Market by Product (Formulation (Semi-solid, Emulsion), Transdermal Patch, Microneedle Patch, Drug-in-adhesive, Matrix Patch), Application (Dermal, Ophthalmic, Nasal, Vaginal, Rectal), End User, Region - Global Forecast to 2030

出版日
ページ情報
英文 435 Pages
納期
即納可能 即納可能とは
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
局所ドラッグデリバリーの世界市場：製品別、用途別、エンドユーザー別、地域別 - 予測（～2030年）
出版日: 2025年08月05日
発行: MarketsandMarkets
ページ情報: 英文 435 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の局所ドラッグデリバリーの市場規模は、2025年の2,684億米ドルから2030年までに4,090億米ドルに達すると予測され、予測期間にCAGRで8.8%の成長が見込まれます。

調査範囲
調査対象年 2024年～2030年
基準年 2024年
予測期間 2025年～2030年
単位 10億米ドル
セグメント 製品、適用部位、エンドユーザー
対象地域 北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ

この市場の成長の主因は、ドライアイ疾患に対する局所処方療法の普及、製薬企業による革新的な経皮ドラッグデリバリーシステムの研究開発への注目の高まり、皮膚感染症の有病率の増加、非侵襲的なドラッグデリバリー方法への選好の高まりと考えられます。

Topical Drug Delivery Market-IMG1

製品別では、半固形製剤が2024年に最大の市場シェアを占めました。

半固形製剤の高いシェアは、副作用が少なく患者の服薬アドヒアランスが高いこと、吸収性が高いこと、薬物放出が効率的であることに起因します。これらの剤形は非脱水性であり、皮膚機能を変化させないため、市場成長が促進されています。

適用部位別では、経皮ドラッグデリバリーセグメントが2024年に最大の市場シェアを占めました。

経皮ドラッグデリバリーセグメントの大きなシェアは、市場での製品上市が増加によるものと考えられます。規制要件が少なく、経鼻や経眼のドラッグデリバリーよりも刺激が少ないことも、市場成長に寄与しています。ナノエマルジョンによる経皮ドラッグデリバリーは、乾癬や白斑などの慢性疾患や自己免疫疾患にも適しています。

地域別では、北米が2024年に最大の市場シェアを占めました。

この地域の大きなシェアは、皮膚疾患の高いリスク、慢性疾患（糖尿病など）の有病率の上昇、避妊薬の使用の増加、老年人口の増加、製薬企業による革新的な経皮ドラッグデリバリーシステムの研究開発への注力などに起因しています。

当レポートでは、世界の局所ドラッグデリバリー市場について調査分析し、主な促進要因と抑制要因、競合情勢、将来の動向などの情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要な知見

  • 局所ドラッグデリバリー市場の概要
  • アジア太平洋の局所ドラッグデリバリー市場：製品別、国別（2024年）
  • 局所ドラッグデリバリー市場：地域の構成
  • 局所ドラッグデリバリー市場：地理的成長機会
  • 局所ドラッグデリバリー市場：先進国市場と新興国市場

第5章 市場の概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 産業動向
    • 経皮ドラッグデリバリーシステムの進歩
    • マイクロニードルパッチ技術の登場
  • 技術分析
    • 主要技術
    • 補完技術
    • 隣接技術
  • ポーターのファイブフォース分析
  • 規制情勢
    • 規制分析
    • 規制機関、政府機関、その他の組織
  • 特許分析
    • 局所ドラッグデリバリーに関する特許公報の動向
    • 考察：管轄区域と主要申請者の分析
  • 貿易分析
  • 価格設定の分析
    • 平均販売価格の動向：製品別（2022年～2024年）
    • 軟膏の平均販売価格：主要企業別（2024年）
    • ジェルの平均販売価格：主要企業別（2024年）
    • 平均販売価格：地域別
    • 半固形製剤の平均販売価格：地域別（2024年）
  • 償還分析
  • 主な会議とイベント（2025年～2026年）
  • 主なステークホルダーと購入基準
  • アンメットニーズ/エンドユーザーの期待
  • 局所ドラッグデリバリー市場におけるAIの影響
  • パイプライン分析
  • エコシステム市場マップ
  • バリューチェーン分析
  • 投資と資金調達のシナリオ
  • 局所ドラッグデリバリー市場に対するトランプ関税の影響
    • イントロダクション
    • 主な関税率
    • 価格の影響の分析
    • さまざまな地域への重要な影響
    • 最終用途産業に対する影響

第6章 局所ドラッグデリバリー市場：製品別

  • イントロダクション
  • 半固形製剤
    • 軟膏
    • クリーム
    • ローション
    • ジェル
    • ペースト
  • 液体製剤
    • 懸濁剤
    • 乳剤
    • 液剤
  • 固形製剤
    • 粉末
    • 坐薬
    • フィルム
  • 経皮製品
    • 経皮パッチ
    • 経皮ゲル
    • 経皮スプレー
  • その他の製品

第7章 局所ドラッグデリバリー市場：適用部位別

  • イントロダクション
  • 皮膚ドラッグデリバリー
  • 眼ドラッグデリバリー
  • 膣ドラッグデリバリー
  • 直腸ドラッグデリバリー
  • 鼻腔ドラッグデリバリー

第8章 局所ドラッグデリバリー市場：エンドユーザー別

  • イントロダクション
  • 在宅ケア環境
  • 病院・診療所
  • 外来手術センター
  • 熱傷ケアセンター
  • その他のエンドユーザー

第9章 局所ドラッグデリバリー市場：地域別

  • イントロダクション
  • 北米
    • 北米のマクロ経済の見通し
    • 米国
    • カナダ
  • 欧州
    • 欧州のマクロ経済の見通し
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • その他の欧州
  • アジア太平洋
    • アジア太平洋のマクロ経済の見通し
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • タイ
    • ベトナム
    • その他のアジア太平洋
  • ラテンアメリカ
    • ラテンアメリカのマクロ経済の見通し
    • ブラジル
    • メキシコ
    • その他のラテンアメリカ
  • 中東・アフリカ
    • 中東・アフリカのマクロ経済の見通し
    • GCC諸国
    • その他の中東・アフリカ

第10章 競合情勢

  • 概要
  • 主要参入企業の戦略/強み
  • 収益分析（2020年～2024年）
  • 市場シェア分析
  • 企業の評価マトリクス：主要企業（2024年）
  • 企業の評価マトリクス：スタートアップ/中小企業（2024年）
  • ブランド/製品の比較
  • 主要企業の研究開発費
  • 企業の評価と財務指標
  • 競合シナリオ

第11章 企業プロファイル

  • 主要企業
    • JOHNSON & JOHNSON SERVICES, INC.
    • GALDERMA
    • BAYER AG
    • NOVARTIS AG
    • ABBVIE INC.
    • GLENMARK PHARMACEUTICALS LIMITED
    • GSK PLC.
    • BAUSCH HEALTH COMPANIES INC.
    • HISAMITSU PHARMACEUTICAL CO., INC.
    • CIPLA
    • VIATRIS INC.
    • ORGANON GROUP OF COMPANIES
    • PFIZER, INC.
    • CRESCITA THERAPEUTICS INC.
    • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • SOLVENTUM
    • LUYE PHARMA GROUP
    • LEAD CHEMICAL CO., LTD.
    • PURDUE PHARMA L.P.
    • LAVIPHARM
  • その他の企業
    • CMP PHARMA, INC.
    • ENCORE DERMATOLOGY, INC.
    • RUSAN PHARMA LTD.
    • ADHEXPHARMA

第12章 付録

図表

List of Tables

  • TABLE 1 STANDARD CURRENCY CONVERSION RATES (USD)
  • TABLE 2 TOPICAL DRUG DELIVERY MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 3 KEY DEVELOPMENTS FOR TRANSDERMAL DRUG DELIVERY SYSTEMS
  • TABLE 4 TOPICAL DRUG DELIVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 5 REGULATORY ADHERENCE FOR TOPICAL DRUG DELIVERY PRODUCTS, BY REGION
  • TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 TOPICAL DRUG DELIVERY MARKET: MAJOR PATENTS
  • TABLE 13 IMPORT DATA FOR HS CODE 300490, BY COUNTRY, 2021-2024 (USD THOUSANDS)
  • TABLE 14 EXPORT DATA FOR HS CODE 300490, BY COUNTRY, 2021-2024 (USD THOUSANDS)
  • TABLE 15 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2022-2024
  • TABLE 16 AVERAGE SELLING PRICE TREND OF OINTMENTS, BY REGION, 2022-2024
  • TABLE 17 AVERAGE SELLING PRICE TREND FOR CREAMS, BY REGION, 2022-2024
  • TABLE 18 AVERAGE SELLING PRICE TREND OF GELS, BY REGION, 2022-2024
  • TABLE 19 TOPICAL DRUG DELIVERY MARKET: KEY CONFERENCES & EVENTS, 2025-2026
  • TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOPICAL DRUG DELIVERY PRODUCTS (%)
  • TABLE 21 KEY BUYING CRITERIA, BY END USER
  • TABLE 22 TOPICAL DRUG DELIVERY FORMULATIONS (GLP-1 ANALOGUES) IN CLINICAL PIPELINE (2024)
  • TABLE 23 TOPICAL DRUG DELIVERY PRODUCTS PROVIDERS: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 25 KEY PRODUCT-RELATED TARIFFS EFFECTIVE FOR TOPICAL DRUG DELIVERY PRODUCTS
  • TABLE 26 NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS
  • TABLE 27 ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS
  • TABLE 28 EUROPE: IMPACT ON GERMANY AND UK DUE TO US TARIFFS
  • TABLE 29 LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS
  • TABLE 30 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 31 KEY PLAYERS OFFERING SEMI-SOLID FORMULATIONS
  • TABLE 32 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 33 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 34 KEY PLAYERS OFFERING OINTMENTS
  • TABLE 35 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
  • TABLE 36 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 37 KEY PLAYERS OFFERING CREAMS
  • TABLE 38 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
  • TABLE 39 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 40 KEY PLAYERS OFFERING LOTIONS
  • TABLE 41 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 42 KEY PLAYERS OFFERING GELS
  • TABLE 43 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
  • TABLE 44 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 45 KEY PLAYERS OFFERING PASTES
  • TABLE 46 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
  • TABLE 47 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 48 KEY PLAYERS OFFERING LIQUID FORMULATIONS
  • TABLE 49 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 50 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 51 KEY PLAYERS OFFERING SUSPENSIONS
  • TABLE 52 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 53 KEY PLAYERS OFFERING EMULSIONS
  • TABLE 54 TOPICAL DRUG DELIVERY MARKET FOR EMULSIONS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 55 KEY PLAYERS OFFERING SOLUTIONS
  • TABLE 56 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 57 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 58 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 59 KEY PLAYERS OFFERING SOLID FORMULATIONS
  • TABLE 60 KEY PLAYERS OFFERING POWDERS
  • TABLE 61 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 62 KEY PLAYERS OFFERING SUPPOSITORIES
  • TABLE 63 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 64 KEY PLAYERS OFFERING FILM
  • TABLE 65 TOPICAL DRUG DELIVERY MARKET FOR FILM, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 66 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 67 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 68 KEY PLAYERS OFFERING TRANSDERMAL PRODUCTS
  • TABLE 69 KEY PLAYERS OFFERING TRANSDERMAL PATCHES
  • TABLE 70 TRANSDERMAL PATCHES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 71 TRANSDERMAL PATCHES MARKET, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
  • TABLE 72 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 73 KEY PLAYERS OFFERING DRUG-IN-ADHESIVE PATCHES
  • TABLE 74 TRANSDERMAL DRUG-IN-ADHESIVE PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 75 KEY PLAYERS OFFERING MATRIX PATCHES
  • TABLE 76 TRANSDERMAL MATRIX PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 77 KEY PLAYERS OFFERING RESERVOIR MEMBRANE PATCHES
  • TABLE 78 TRANSDERMAL RESERVOIR MEMBRANE PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 79 KEY PLAYERS OFFERING MICRONEEDLE PATCHES
  • TABLE 80 TRANSDERMAL MICRONEEDLE PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 81 KEY PLAYERS OFFERING IONTOPHORESIS PATCHES
  • TABLE 82 TRANSDERMAL IONTOPHORESIS PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 83 KEY PLAYERS OFFERING VAPOR PATCHES
  • TABLE 84 TRANSDERMAL VAPOR PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 85 KEY PLAYERS OFFERING TRANSDERMAL GELS
  • TABLE 86 TRANSDERMAL GELS MARKET, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
  • TABLE 87 TRANSDERMAL GELS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 88 KEY PLAYERS OFFERING TRANSDERMAL SPRAYS
  • TABLE 89 TRANSDERMAL SPRAYS MARKET, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
  • TABLE 90 TRANSDERMAL SPRAYS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 91 TOPICAL DRUG DELIVERY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 92 KEY PLAYERS OFFERING OTHER PRODUCTS
  • TABLE 93 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 94 KEY PLAYERS OFFERING DERMAL DRUG DELIVERY PRODUCTS
  • TABLE 95 DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 96 KEY PLAYERS OFFERING OPHTHALMIC DRUG DELIVERY PRODUCTS
  • TABLE 97 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 98 KEY PLAYERS OFFERING VAGINAL DRUG DELIVERY PRODUCTS
  • TABLE 99 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 100 KEY PLAYERS OFFERING RECTAL DRUG DELIVERY PRODUCTS
  • TABLE 101 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 102 KEY PLAYERS OFFERING NASAL DRUG DELIVERY PRODUCTS
  • TABLE 103 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 104 TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 105 TOPICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 106 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 107 TOPICAL DRUG DELIVERY MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 108 TOPICAL DRUG DELIVERY MARKET FOR BURN CARE CENTERS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 109 TOPICAL DRUG DELIVERY MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 110 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2023-2030 (USD BILLION)
  • TABLE 111 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 112 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 113 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 114 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 115 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 116 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 117 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 118 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 119 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 120 US: KEY MACROINDICATORS
  • TABLE 121 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 122 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 123 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 124 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 125 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 126 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 127 US: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 128 US: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 129 CANADA: KEY MACROINDICATORS
  • TABLE 130 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 131 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 132 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 133 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 134 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 135 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 136 CANADA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 137 CANADA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 138 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 139 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 140 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 141 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 142 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 143 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 144 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 145 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 146 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 147 GERMANY: KEY MACROINDICATORS
  • TABLE 148 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 149 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 150 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 151 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 152 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 153 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 154 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 155 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 156 UK: KEY MACROINDICATORS
  • TABLE 157 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 158 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 159 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 160 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 161 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 162 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 163 UK: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 164 UK: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 165 FRANCE: KEY MACROINDICATORS
  • TABLE 166 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 167 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 168 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 169 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 170 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 171 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 172 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 173 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 174 ITALY: KEY MACROINDICATORS
  • TABLE 175 ITALY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 176 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 177 ITALY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 178 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 179 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 180 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 181 ITALY: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 182 ITALY: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 183 SPAIN: KEY MACROINDICATORS
  • TABLE 184 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 185 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 186 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 187 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 188 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 189 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 190 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 191 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 192 NETHERLANDS: KEY MACROINDICATORS
  • TABLE 193 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 194 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 195 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 196 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 197 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 198 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 199 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 200 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 201 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 202 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 203 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 204 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 205 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 206 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 207 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 208 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 209 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 210 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 211 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 212 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 213 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 214 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 215 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 216 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 217 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 218 CHINA: MACROECONOMIC INDICATORS
  • TABLE 219 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 220 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 221 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 222 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 223 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 224 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 225 CHINA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 226 CHINA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 227 JAPAN: MACROECONOMIC INDICATORS
  • TABLE 228 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 229 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 230 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 231 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 232 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 233 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 234 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 235 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 236 INDIA: MACROECONOMIC INDICATORS
  • TABLE 237 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 238 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 239 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 240 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 241 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 242 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 243 INDIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 244 INDIA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 245 AUSTRALIA: KEY MACROINDICATORS
  • TABLE 246 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 247 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 248 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 249 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 250 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 251 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 252 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 253 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 254 SOUTH KOREA: MACROECONOMIC INDICATORS
  • TABLE 255 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 256 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 257 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 258 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 259 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 260 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 261 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 262 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 263 THAILAND: MACROECONOMIC INDICATORS
  • TABLE 264 THAILAND: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 265 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 266 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 267 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 268 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 269 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 270 THAILAND: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 271 THAILAND: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 272 VIETNAM: MACROECONOMIC INDICATORS
  • TABLE 273 VIETAM: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 274 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 275 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 276 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 277 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 278 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 279 VIETAM: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 280 VIETAM: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 281 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 282 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 283 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 284 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 285 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 286 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 287 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 288 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 289 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 290 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 291 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 292 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 293 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 294 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 295 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 296 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 297 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 298 BRAZIL: MACROECONOMIC INDICATORS
  • TABLE 299 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 300 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 301 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 302 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 303 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 304 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 305 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 306 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 307 MEXICO: MACROECONOMIC INDICATORS
  • TABLE 308 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 309 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 310 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 311 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 312 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 313 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 314 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 315 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 316 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 317 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 318 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 319 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 320 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 321 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 322 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 323 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 324 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY REGION, 2023-2030 (USD BILLION)
  • TABLE 325 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 326 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 327 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 328 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 329 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 330 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 331 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 332 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 333 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 334 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 335 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 336 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 337 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 338 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 339 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 340 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 341 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 342 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS
  • TABLE 343 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 344 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 345 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 346 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 347 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 348 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 349 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 350 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 351 UNITED ARAB EMIRATES: KEY MACROINDICATORS
  • TABLE 352 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 353 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 354 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 355 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 356 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 357 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 358 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 359 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 360 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 361 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 362 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 363 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 364 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 365 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 366 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 367 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 368 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 369 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 370 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 371 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 372 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 373 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 374 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 375 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 376 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET
  • TABLE 377 TOPICAL DRUG DELIVERY MARKET: DEGREE OF COMPETITION
  • TABLE 378 TOPICAL DRUG DELIVERY MARKET: REGION FOOTPRINT
  • TABLE 379 TOPICAL DRUG DELIVERY MARKET: PRODUCT TYPE FOOTPRINT
  • TABLE 380 TOPICAL DRUG DELIVERY MARKET: SITE OF APPLICATION FOOTPRINT
  • TABLE 381 TOPICAL DRUG DELIVERY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
  • TABLE 382 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 383 TOPICAL DRUG DELIVERY MARKET: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 384 TOPICAL DRUG DELIVERY MARKET: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 385 TOPICAL DRUG DELIVERY MARKET: EXPANSIONS, JANUARY 2022-JUNE 2025
  • TABLE 386 TOPICAL DRUG DELIVERY MARKET: OTHERS, JANUARY 2022-JUNE 2025
  • TABLE 387 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
  • TABLE 388 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
  • TABLE 389 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 390 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 391 GALDERMA: COMPANY OVERVIEW
  • TABLE 392 GALDERMA: PRODUCTS OFFERED
  • TABLE 393 GALDERMA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 394 GALDERMA: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 395 GALDERMA: EXPANSIONS, JANUARY 2022-JUNE 2025
  • TABLE 396 BAYER AG: COMPANY OVERVIEW
  • TABLE 397 BAYER AG: PRODUCTS OFFERED
  • TABLE 398 BAYER AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 399 BAYER AG: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 400 NOVARTIS AG: COMPANY OVERVIEW
  • TABLE 401 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 402 NOVARTIS AG: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 403 NOVARTIS AG: OTHERS, JANUARY 2022-JUNE 2025
  • TABLE 404 ABBVIE INC.: COMPANY OVERVIEW
  • TABLE 405 ABBVIE, INC.: PRODUCTS OFFERED
  • TABLE 406 ABBVIE INC.: PRODUCT LAUNCHES, JANUARY 2022-JUNE 2025
  • TABLE 407 ABBVIE, INC.: EXPANSIONS, JANUARY 2022-JUNE 2025
  • TABLE 408 ABBVIE INC.: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
  • TABLE 409 GLENMARK PHARMACEUTICALS LIMITED: COMPANY OVERVIEW
  • TABLE 410 GLENMARK PHARMACEUTICALS LIMITED: PRODUCTS OFFERED
  • TABLE 411 GLENMARK PHARMACEUTICALS LIMITED: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 412 GLENMARK PHARMACEUTICALS LIMITED: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 413 GSK PLC.: COMPANY OVERVIEW
  • TABLE 414 GSK PLC.: PRODUCTS OFFERED
  • TABLE 415 GSK PLC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 416 GSK PLC.: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
  • TABLE 417 BAUSCH HEALTH COMPANIES INC.: COMPANY OVERVIEW
  • TABLE 418 BAUSCH HEALTH COMPANIES, INC.: PRODUCTS OFFERED
  • TABLE 419 BAUSCH HEALTH COMPANIES INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 420 BAUSCH HEALTH COMPANIES INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 421 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY OVERVIEW
  • TABLE 422 HISAMITSU PHARMACEUTICAL CO., INC.: PRODUCTS OFFERED
  • TABLE 423 HISAMITSU PHARMACEUTICAL CO., INC.: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 424 HISAMITSU PHARMACEUTICAL CO., INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 425 HISAMITSU PHARMACEUTICAL CO., INC.: EXPANSIONS, JANUARY 2022-JUNE 2025
  • TABLE 426 CIPLA: COMPANY OVERVIEW
  • TABLE 427 CIPLA: PRODUCTS OFFERED
  • TABLE 428 CIPLA: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 429 VIATRIS INC.: COMPANY OVERVIEW
  • TABLE 430 VIATRIS INC.: PRODUCTS OFFERED
  • TABLE 431 VIATRIS INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 432 VIATRIS INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 433 VIATRIS INC.: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
  • TABLE 434 ORGANON GROUP OF COMPANIES: COMPANY OVERVIEW
  • TABLE 435 ORGANON GROUP OF COMPANIES: PRODUCTS OFFERED
  • TABLE 436 ORGANON GROUP OF COMPANIES: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 437 ORGANON GROUP OF COMPANIES: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 438 PFIZER INC.: COMPANY OVERVIEW
  • TABLE 439 PFIZER INC.: PRODUCTS OFFERED
  • TABLE 440 PFIZER, INC.: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 441 PFIZER, INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 442 CRESCITA THERAPEUTICS INC.: COMPANY OVERVIEW
  • TABLE 443 CRESCITA THERAPEUTICS INC.: PRODUCTS OFFERED
  • TABLE 444 CRESCITA THERAPEUTICS INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 445 CRESCITA THERAPEUTICS INC.: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
  • TABLE 446 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
  • TABLE 447 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED
  • TABLE 448 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 449 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2022-APRIL 2025
  • TABLE 450 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
  • TABLE 451 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
  • TABLE 452 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 453 SOLVENTUM: COMPANY OVERVIEW
  • TABLE 454 SOLVENTUM: PRODUCTS OFFERED
  • TABLE 455 SOLVENTUM DEALS, JANUARY 2022-JUNE 2025
  • TABLE 456 LUYE PHARMA GROUP: COMPANY OVERVIEW
  • TABLE 457 LUYE PHARMA GROUP: PRODUCTS OFFERED
  • TABLE 458 LUYE PHARMA GROUP: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 459 LUYE PHARMA GROUP: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 460 LEAD CHEMICAL CO., LTD.: COMPANY OVERVIEW
  • TABLE 461 PURDUE PHARMA L.P.: COMPANY OVERVIEW
  • TABLE 462 PURDUE PHARMA L.P.: PRODUCTS OFFERED
  • TABLE 463 LAVIPHARM: COMPANY OVERVIEW
  • TABLE 464 LAVIPHARM: PRODUCTS OFFERED
  • TABLE 465 CMP PHARMA, INC.: COMPANY OVERVIEW
  • TABLE 466 ENCORE DERMATOLOGY, INC.: COMPANY OVERVIEW
  • TABLE 467 RUSAN PHARMA LTD.: COMPANY OVERVIEW
  • TABLE 468 ADHEXPHARMA: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 TOPICAL DRUG DELIVERY MARKET & REGIONAL SEGMENTATION
  • FIGURE 2 TOPICAL DRUG DELIVERY MARKET: RESEARCH DESIGN
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE PARTICIPANTS
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
  • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
  • FIGURE 7 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
  • FIGURE 8 TOPICAL DRUG DELIVERY MARKET - REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON
  • FIGURE 9 REVENUE ANALYSIS OF TOP FIVE COMPANIES: TOPICAL DRUG DELIVERY MARKET (2024)
  • FIGURE 10 PHARMACEUTICAL SALES APPROACH
  • FIGURE 11 TOP-DOWN APPROACH
  • FIGURE 12 BOTTOM-UP APPROACH
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN TOPICAL DRUG DELIVERY MARKET (2025-2030): IMPACT ON MARKET GROWTH & CAGR)
  • FIGURE 14 CAGR PROJECTIONS
  • FIGURE 15 DATA TRIANGULATION METHODOLOGY
  • FIGURE 16 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2025 VS. 2030 (USD BILLION)
  • FIGURE 17 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2025 VS. 2030 (USD BILLION)
  • FIGURE 18 TOPICAL DRUG DELIVERY MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)
  • FIGURE 19 GEOGRAPHIC SNAPSHOT OF TOPICAL DRUG DELIVERY MARKET
  • FIGURE 20 INCREASING PREVALENCE OF SKIN DISORDERS AND RISING INCIDENCE OF BURN INJURIES TO PROPEL MARKET
  • FIGURE 21 SEMI-SOLID FORMULATIONS SEGMENT IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2024
  • FIGURE 22 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 23 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 24 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
  • FIGURE 25 TOPICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 26 BIOPHARMACEUTICAL R&D SPENDING (2020-2026)
  • FIGURE 27 TOP PHARMA R&D INVESTMENTS: LEADING COMPANY INVESTMENTS, 2023
  • FIGURE 28 TOPICAL DRUG DELIVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 29 TOPICAL DRUG DELIVERY MARKET: NUMBER OF GRANTED PATENT APPLICATIONS (JANUARY 2014-JUNE 2025)
  • FIGURE 30 TOP APPLICANT COUNTRIES/REGIONS FOR TOPICAL DRUG DELIVERY PATENTS (JANUARY 2014-JUNE 2025)
  • FIGURE 31 AVERAGE SELLING PRICE OF OINTMENTS, BY KEY PLAYER, 2024
  • FIGURE 32 AVERAGE SELLING PRICE OF GELS, BY KEY PLAYER, 2024
  • FIGURE 33 AVERAGE SELLING PRICE OF SEMI-SOLID FORMULATIONS, BY REGION, 2024
  • FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOPICAL DRUG DELIVERY PRODUCTS
  • FIGURE 35 KEY BUYING CRITERIA FOR TOPICAL DRUG DELIVERY PRODUCTS, BY TOP THREE END USERS
  • FIGURE 36 AI-USE CASES
  • FIGURE 37 TOPICAL DRUG DELIVERY MARKET: ECOSYSTEM MAP
  • FIGURE 38 TOPICAL DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 39 TOPICAL DRUG DELIVERY MARKET: INVESTMENT & FUNDING SCENARIO, 2020-2024
  • FIGURE 40 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 41 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
  • FIGURE 42 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
  • FIGURE 43 REVENUE ANALYSIS OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET, 2022-2024
  • FIGURE 44 TOPICAL DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 45 RANKING OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET, 2024
  • FIGURE 46 TOPICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 47 TOPICAL DRUG DELIVERY MARKET: COMPANY FOOTPRINT
  • FIGURE 48 TOPICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 49 TOPICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 50 R&D EXPENDITURE OF KEY PLAYERS, 2022-2024
  • FIGURE 51 EV/EBITDA OF KEY VENDORS
  • FIGURE 52 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 53 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 54 GALDERMA: COMPANY SNAPSHOT (2024)
  • FIGURE 55 BAYER AG: COMPANY SNAPSHOT (2024)
  • FIGURE 56 NOVARTIS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 57 ABBVIE, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 58 GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2024)
  • FIGURE 59 GSK PLC.: COMPANY SNAPSHOT (2024)
  • FIGURE 60 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 61 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 62 CIPLA: COMPANY SNAPSHOT (2024)
  • FIGURE 63 VIATRIS INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 64 ORGANON GROUP OF COMPANIES: COMPANY SNAPSHOT (2024)
  • FIGURE 65 PFIZER, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 66 CRESCITA THERAPEUTICS INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 67 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2024)
  • FIGURE 68 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 69 SOLVENTUM: COMPANY SNAPSHOT (2024)
  • FIGURE 70 LUYE PHARMA GROUP: COMPANY SNAPSHOT (2023)
  • FIGURE 71 COMPANY SNAPSHOT: LAVIPHARM (2024)
目次
Product Code: PH 7545

The global topical drug delivery market is expected to reach USD 409.0 billion by 2030 from USD 268.4 billion in 2025, at a CAGR of 8.8% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD billion)
SegmentsProduct, Site of Application, and End User
Regions coveredNorth America, Europe, APAC, LATAM, MEA

The growth of this market can largely be attributed to the uptake of topical prescription therapy for dry eye diseases, the growing focus of pharmaceutical companies on the R&D of innovative transdermal drug delivery systems, the increasing prevalence of skin infections, and the rising preference for non-invasive drug delivery methods.

Topical Drug Delivery Market - IMG1

By product, the semi-solid formulations segment accounted for the largest market share in 2024.

By product, the topical drug delivery market is segmented into semi-solid formulations, liquid formulations, solid formulations, transdermal products, and other products. The large share of the semi-solid formulations segment is attributed to enhanced patient adherence with limited side effects, high absorption, and efficient provision of drug release. These dosage forms are non-dehydrating and do not modify skin functioning, fueling market growth.

By site of application, the dermal drug delivery segment accounted for the largest market share in 2024.

By site of application, the market is segmented into dermal drug delivery, ophthalmic drug delivery, rectal drug delivery, vaginal drug delivery, and nasal drug delivery. The large share of the dermal drug delivery segment can be attributed to the increasing product launches in the market. Fewer regulatory requirements and lower irritation than nasal or ophthalmic drug delivery also contribute to market growth. Dermal drug delivery through nanoemulsions is also suitable for chronic and autoimmune diseases, such as psoriasis and vitiligo.

By region, North America accounted for the largest market share in 2024.

By region, North America accounted for the largest share of the market in 2024. The large share of this region is attributed to the high risk of skin disorders, the rising prevalence of chronic diseases (such as diabetes), increasing use of contraceptives, the increasing geriatric population, and the growing focus of pharmaceutical companies on the R&D of innovative transdermal drug delivery systems.

Breakdown of supply-side primary interviews:

  • By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%)
  • By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%)
  • By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Breakdown of demand-side primary interviews:

  • By Company Type: Hospitals & Clinics (60%), Ambulatory Surgery Centers (25%), and Home Care Settings (15%)
  • By Designation: Directors (35%), Vice Presidents (27%), Managers (22%), and Other Designations (16%)
  • By Region: North America (40%), Europe (25%), the Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Key players in the Topical Drug Delivery Market

The prominent players in the topical drug delivery market are Johnson & Johnson Private Limited (US), Galderma (Switzerland), Bayer AG (Germany), Novartis International AG (Switzerland), AbbVie Inc. (US), GSK Plc. (UK), Bausch Health Companies Inc. (Canada), Glenmark Pharmaceuticals Ltd. (India), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Boehringer Ingelheim International GmbH (Germany), Pfizer Inc. (US), Teva Pharmaceuticals Industries Ltd. (Israel), Viatris Inc. (US), Organon group of companies (US), Solventum (US), Crescita Therapeutics Inc. (Canada), Luye Pharma Group (China), Lead Chemical Co., Ltd. (Japan), Purdue Pharma L.P. (US), Lavipharm (Greece), CMP Pharma, Inc. (Germany), Encore Dermatology, Inc. (US), Rusan Pharma Ltd. (India), and AdhexPharma (France).

Research Coverage:

The report analyzes the topical drug delivery market. It aims to estimate the market size and future growth potential of this market based on various segments such as product, site of application, end user, and region. The report also includes a product portfolio matrix of various topical drug delivery products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which in turn would help them garner a more significant share of the market. Firms purchasing the report could use one or any combination of the following strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the topical drug delivery market. The report analyzes this market by product, site of application, and end users.
  • Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the topical drug delivery market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various topical drug delivery products across regions.
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the topical drug delivery market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the topical drug delivery market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
    • 1.2.2 MARKETS & REGIONS COVERED
    • 1.2.3 YEARS CONSIDERED
    • 1.2.4 CURRENCY CONSIDERED
  • 1.3 MARKET STAKEHOLDERS
  • 1.4 LIMITATIONS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH METHODOLOGY DESIGN
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Key data from primary sources
      • 2.2.2.2 Key industry insights
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 APPROACH 1: REVENUE SHARE ANALYSIS
    • 2.3.2 APPROACH 2: PHARMACEUTICAL SALES ANALYSIS
    • 2.3.3 APPROACH 3: TOP-DOWN APPROACH
    • 2.3.4 APPROACH 4: BOTTOM-UP APPROACH
    • 2.3.5 APPROACH 4: PRIMARY INTERVIEWS
    • 2.3.6 APPROACH 5: DEMAND-SIDE APPROACH
    • 2.3.7 APPROACH 6: VOLUME DATA ANALYSIS
  • 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
  • 2.5 MARKET SHARE ANALYSIS
  • 2.6 STUDY ASSUMPTIONS
    • 2.6.1 GROWTH RATE ASSUMPTIONS
  • 2.7 RISK ASSESSMENT
  • 2.8 LIMITATIONS
    • 2.8.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.8.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW
  • 4.2 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT & COUNTRY (2024)
  • 4.3 TOPICAL DRUG DELIVERY MARKET: REGIONAL MIX
  • 4.4 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.5 TOPICAL DRUG DELIVERY MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing prevalence of skin disorders
      • 5.2.1.2 High incidence of burn injuries
      • 5.2.1.3 Growing emphasis on patient convenience
      • 5.2.1.4 Increasing investments in pharmaceutical R&D
      • 5.2.1.5 Rising incidence of chronic diseases
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Adverse skin reactions & allergies
      • 5.2.2.2 Drug failure & recalls of TDD systems
      • 5.2.2.3 High development costs of topical drug delivery products
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing preference for self-administration and home care
      • 5.2.3.2 High growth potential of emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Technical barriers related to skin irritation & permeability
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 ADVANCES IN TRANSDERMAL DRUG DELIVERY SYSTEMS
    • 5.3.2 EMERGENCE OF MICRONEEDLE PATCH TECHNOLOGIES
  • 5.4 TECHNOLOGY ANALYSIS
    • 5.4.1 KEY TECHNOLOGIES
      • 5.4.1.1 Nanocarrier-based delivery systems
      • 5.4.1.2 Microemulsions & nanoemulsion
      • 5.4.1.3 Thermosensitive & pH-sensitive hydrogels & hydrocolloids
    • 5.4.2 COMPLEMENTARY TECHNOLOGIES
      • 5.4.2.1 Microneedle-enhanced delivery
      • 5.4.2.2 AI-assisted formulations & prediction models
    • 5.4.3 ADJACENT TECHNOLOGIES
      • 5.4.3.1 Wearable sensor-integrated topical patches
      • 5.4.3.2 3D testing skin models
  • 5.5 PORTER'S FIVE FORCES ANALYSIS
    • 5.5.1 THREAT OF NEW ENTRANTS
    • 5.5.2 THREAT OF SUBSTITUTES
    • 5.5.3 BARGAINING POWER OF SUPPLIERS
    • 5.5.4 BARGAINING POWER OF BUYERS
    • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.6 REGULATORY LANDSCAPE
    • 5.6.1 REGULATORY ANALYSIS
    • 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.7 PATENT ANALYSIS
    • 5.7.1 PATENT PUBLICATION TRENDS FOR TOPICAL DRUG DELIVERY
    • 5.7.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS
  • 5.8 TRADE ANALYSIS
    • 5.8.1 TRADE DATA FOR HS CODE 300490
      • 5.8.1.1 Import data for HS Code 300490
      • 5.8.1.2 Export data for HS Code 300490
  • 5.9 PRICING ANALYSIS
    • 5.9.1 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2022-2024
    • 5.9.2 AVERAGE SELLING PRICE OF OINTMENTS, BY KEY PLAYER, 2024
    • 5.9.3 AVERAGE SELLING PRICE OF GELS, BY KEY PLAYER, 2024
    • 5.9.4 AVERAGE SELLING PRICE, BY REGION
    • 5.9.5 AVERAGE SELLING PRICE OF SEMI-SOLID FORMULATIONS, BY REGION, 2024
      • 5.9.5.1 Average selling price trend of ointments, by region, 2022-2024
      • 5.9.5.2 Average selling price trend of creams, by region, 2022-2024
      • 5.9.5.3 Average selling price trend of gels, by region, 2022-2024
  • 5.10 REIMBURSEMENT ANALYSIS
  • 5.11 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.12.2 BUYING CRITERIA
  • 5.13 UNMET NEEDS/END-USER EXPECTATIONS
  • 5.14 IMPACT OF AI ON TOPICAL DRUG DELIVERY MARKET
    • 5.14.1 AI-USE CASES
  • 5.15 PIPELINE ANALYSIS
  • 5.16 ECOSYSTEM MARKET MAP
  • 5.17 VALUE CHAIN ANALYSIS
  • 5.18 INVESTMENT & FUNDING SCENARIO
  • 5.19 TRUMP TARIFF IMPACT ON TOPICAL DRUG DELIVERY MARKET
    • 5.19.1 INTRODUCTION
    • 5.19.2 KEY TARIFF RATES
    • 5.19.3 PRICE IMPACT ANALYSIS
    • 5.19.4 KEY IMPACT ON VARIOUS REGIONS
    • 5.19.5 END-USE INDUSTRY IMPACT

6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 SEMI-SOLID FORMULATIONS
    • 6.2.1 OINTMENTS
      • 6.2.1.1 Wide applications in analgesic indications to drive market
    • 6.2.2 CREAMS
      • 6.2.2.1 High absorption capabilities to boost demand
    • 6.2.3 LOTIONS
      • 6.2.3.1 Convenient application to fuel uptake
    • 6.2.4 GELS
      • 6.2.4.1 Enhanced patient compliance and aesthetic appeal to drive market
    • 6.2.5 PASTES
      • 6.2.5.1 Prevention of skin irritation to fuel uptake
  • 6.3 LIQUID FORMULATIONS
    • 6.3.1 SUSPENSIONS
      • 6.3.1.1 Higher rate of bioavailability and controlled onset of action to drive market
    • 6.3.2 EMULSIONS
      • 6.3.2.1 Versatile carriers for enhanced drug delivery to fuel uptake
    • 6.3.3 SOLUTIONS
      • 6.3.3.1 Uniform & rapid drug delivery to boost demand
  • 6.4 SOLID FORMULATIONS
    • 6.4.1 POWDERS
      • 6.4.1.1 Inexpensive manufacturing and effectiveness against antifungal infections to propel market
    • 6.4.2 SUPPOSITORIES
      • 6.4.2.1 Ability to ensure drug compatibility to fuel market
    • 6.4.3 FILM
      • 6.4.3.1 Next-generation advancements to boost demand
  • 6.5 TRANSDERMAL PRODUCTS
    • 6.5.1 TRANSDERMAL PATCHES
      • 6.5.1.1 Drug-in-adhesive patches
        • 6.5.1.1.1 Enhanced drug release to fuel uptake
      • 6.5.1.2 Matrix patches
        • 6.5.1.2.1 Rising technological advancements to boost demand
      • 6.5.1.3 Reservoir membrane patches
        • 6.5.1.3.1 Prolonged drug delivery to fuel market
      • 6.5.1.4 Microneedle patches
        • 6.5.1.4.1 Ability to deliver APIs to support market growth
      • 6.5.1.5 Iontophoresis patches
        • 6.5.1.5.1 Low molecular weight patches to support market growth
      • 6.5.1.6 Vapor patches
        • 6.5.1.6.1 Ability to release essential oils to support market growth
    • 6.5.2 TRANSDERMAL GELS
      • 6.5.2.1 Rapid release of drugs to fuel uptake
    • 6.5.3 TRANSDERMAL SPRAYS
      • 6.5.3.1 Targeted approach to boost demand
  • 6.6 OTHER PRODUCTS

7 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 DERMAL DRUG DELIVERY
    • 7.2.1 STANDARD MEDIUM WITH HIGH DRUG ABSORPTION TO PROPEL MARKET
  • 7.3 OPHTHALMIC DRUG DELIVERY
    • 7.3.1 FOCUS ON MICROEMULSION-BASED FORMULATIONS TO BOOST DEMAND
  • 7.4 VAGINAL DRUG DELIVERY
    • 7.4.1 LIMITED INTERVENTION BY MEDICAL PERSONNEL TO DRIVE MARKET
  • 7.5 RECTAL DRUG DELIVERY
    • 7.5.1 COMBINATION OF LOCAL & SYSTEMIC THERAPY OF DRUGS TO FUEL UPTAKE
  • 7.6 NASAL DRUG DELIVERY
    • 7.6.1 QUICK ONSET OF DRUG ACTION & CONVENIENCE TO SUPPORT MARKET UPTAKE

8 TOPICAL DRUG DELIVERY MARKET, BY END USER

  • 8.1 INTRODUCTION
  • 8.2 HOME CARE SETTINGS
    • 8.2.1 HIGH PREFERENCE, AFFORDABILITY, AND CONVENIENCE TO PROPEL MARKET
  • 8.3 HOSPITALS & CLINICS
    • 8.3.1 ADOPTION OF TOPICAL ANAESTHETICS FOR MEDICAL & SURGICAL SUB-SPECIALTIES TO DRIVE MARKET
  • 8.4 AMBULATORY SURGERY CENTERS
    • 8.4.1 UTILIZATION OF ANTIMICROBIAL TOPICAL DRUGS FOR TRAUMA CASES TO BOOST DEMAND
  • 8.5 BURN CARE CENTERS
    • 8.5.1 HIGH INCIDENCE OF BURN INJURIES AND UPTAKE OF OINTMENTS TO SUPPORT MARKET GROWTH
  • 8.6 OTHER END USERS

9 TOPICAL DRUG DELIVERY MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 9.2.2 US
      • 9.2.2.1 Rising prevalence of skin diseases to drive market
    • 9.2.3 CANADA
      • 9.2.3.1 Rising prevalence of hypertension and funding for topical drugs research to drive market growth
  • 9.3 EUROPE
    • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 9.3.2 GERMANY
      • 9.3.2.1 Growing focus of R&D for pharmaceutical API development to boost demand
    • 9.3.3 UK
      • 9.3.3.1 Rising demand for painless treatment alternatives to fuel market
    • 9.3.4 FRANCE
      • 9.3.4.1 Rising incidence of diabetes and subsequent increase in skin lesions to drive market
    • 9.3.5 ITALY
      • 9.3.5.1 Rising demand for transdermal patches to propel market
    • 9.3.6 SPAIN
      • 9.3.6.1 Expanding research hub to fuel market
    • 9.3.7 NETHERLANDS
      • 9.3.7.1 Public awareness initiatives for preventive care to fuel uptake
    • 9.3.8 REST OF EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 9.4.2 CHINA
      • 9.4.2.1 Rising cases of communicable diseases to drive market
    • 9.4.3 JAPAN
      • 9.4.3.1 Increasing number of product approvals to drive market
    • 9.4.4 INDIA
      • 9.4.4.1 Growing focus on adoption of non-invasive drug delivery methods to drive market
    • 9.4.5 AUSTRALIA
      • 9.4.5.1 Increasing number of smokers to fuel uptake
    • 9.4.6 SOUTH KOREA
      • 9.4.6.1 Favorable government focus on expanding clinical trials to boost demand
    • 9.4.7 THAILAND
      • 9.4.7.1 Regulatory reforms and supportive healthcare initiatives to support market growth
    • 9.4.8 VIETNAM
      • 9.4.8.1 Increasing investments and regulatory reforms to fuel uptake
    • 9.4.9 REST OF ASIA PACIFIC
  • 9.5 LATIN AMERICA
    • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 9.5.2 BRAZIL
      • 9.5.2.1 High prevalence of diabetes to propel market growth
    • 9.5.3 MEXICO
      • 9.5.3.1 Increasing prevalence of glaucoma to drive market
    • 9.5.4 REST OF LATIN AMERICA
  • 9.6 MIDDLE EAST & AFRICA
    • 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 9.6.2 GCC COUNTRIES
      • 9.6.2.1 Kingdom of Saudi Arabia (KSA)
        • 9.6.2.1.1 Expanding healthcare infrastructure to boost demand
      • 9.6.2.2 United Arab Emirates (UAE)
        • 9.6.2.2.1 Increasing prevalence of diabetes to fuel uptake
      • 9.6.2.3 Other GCC Countries
    • 9.6.3 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET
  • 10.3 REVENUE ANALYSIS, 2020-2024
  • 10.4 MARKET SHARE ANALYSIS
    • 10.4.1 RANKING OF KEY MARKET PLAYERS
  • 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 10.5.1 STARS
    • 10.5.2 EMERGING LEADERS
    • 10.5.3 PERVASIVE PLAYERS
    • 10.5.4 PARTICIPANTS
    • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 10.5.5.1 Company footprint
      • 10.5.5.2 Region footprint
      • 10.5.5.3 Product footprint
      • 10.5.5.4 Site of application footprint
  • 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 10.6.1 PROGRESSIVE COMPANIES
    • 10.6.2 RESPONSIVE COMPANIES
    • 10.6.3 DYNAMIC COMPANIES
    • 10.6.4 STARTING BLOCKS
    • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 10.6.5.1 Detailed list of key startups/SME players
      • 10.6.5.2 Competitive benchmarking of key emerging players/startups
  • 10.7 BRAND/PRODUCT COMPARISON
    • 10.7.1 TOPICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 10.8 R&D EXPENDITURE OF KEY PLAYERS
    • 10.8.1 R&D EXPENDITURE OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET
  • 10.9 COMPANY VALUATION & FINANCIAL METRICS
    • 10.9.1 FINANCIAL METRICS
    • 10.9.2 COMPANY VALUATION
  • 10.10 COMPETITIVE SCENARIO
    • 10.10.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
    • 10.10.2 DEALS
    • 10.10.3 EXPANSIONS
    • 10.10.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES

  • 11.1 KEY PLAYERS
    • 11.1.1 JOHNSON & JOHNSON SERVICES, INC.
      • 11.1.1.1 Business overview
      • 11.1.1.2 Products offered
      • 11.1.1.3 Recent developments
        • 11.1.1.3.1 Product approvals
        • 11.1.1.3.2 Deals
      • 11.1.1.4 MnM view
        • 11.1.1.4.1 Key strengths
        • 11.1.1.4.2 Strategic choices
        • 11.1.1.4.3 Weaknesses & competitive threats
    • 11.1.2 GALDERMA
      • 11.1.2.1 Business overview
      • 11.1.2.2 Products offered
      • 11.1.2.3 Recent developments
        • 11.1.2.3.1 Product launches & approvals
        • 11.1.2.3.2 Deals
        • 11.1.2.3.3 Expansions
      • 11.1.2.4 MnM view
        • 11.1.2.4.1 Key strengths
        • 11.1.2.4.2 Strategic choices
        • 11.1.2.4.3 Weaknesses & competitive threats
    • 11.1.3 BAYER AG
      • 11.1.3.1 Business overview
      • 11.1.3.2 Products offered
      • 11.1.3.3 Recent developments
        • 11.1.3.3.1 Product launches & approvals
        • 11.1.3.3.2 Deals
      • 11.1.3.4 MnM view
        • 11.1.3.4.1 Key strengths
        • 11.1.3.4.2 Strategic choices
        • 11.1.3.4.3 Weaknesses & competitive threats
    • 11.1.4 NOVARTIS AG
      • 11.1.4.1 Business overview
      • 11.1.4.2 Products offered
      • 11.1.4.3 Recent developments
        • 11.1.4.3.1 Deals
        • 11.1.4.3.2 Other developments
      • 11.1.4.4 MnM view
        • 11.1.4.4.1 Key strengths
        • 11.1.4.4.2 Strategic choices
        • 11.1.4.4.3 Weaknesses & competitive threats
    • 11.1.5 ABBVIE INC.
      • 11.1.5.1 Business overview
      • 11.1.5.2 Products offered
      • 11.1.5.3 Recent developments
        • 11.1.5.3.1 Product launches
        • 11.1.5.3.2 Expansions
        • 11.1.5.3.3 Other developments
      • 11.1.5.4 MnM view
        • 11.1.5.4.1 Key strengths
        • 11.1.5.4.2 Strategic choices
        • 11.1.5.4.3 Weaknesses & competitive threats
    • 11.1.6 GLENMARK PHARMACEUTICALS LIMITED
      • 11.1.6.1 Business overview
      • 11.1.6.2 Products offered
      • 11.1.6.3 Recent developments
        • 11.1.6.3.1 Product approvals
        • 11.1.6.3.2 Deals
    • 11.1.7 GSK PLC.
      • 11.1.7.1 Business overview
      • 11.1.7.2 Products offered
      • 11.1.7.3 Recent developments
        • 11.1.7.3.1 Deals
        • 11.1.7.3.2 Other developments
    • 11.1.8 BAUSCH HEALTH COMPANIES INC.
      • 11.1.8.1 Business overview
      • 11.1.8.2 Products offered
      • 11.1.8.3 Recent developments
        • 11.1.8.3.1 Product launches & approvals
        • 11.1.8.3.2 Deals
    • 11.1.9 HISAMITSU PHARMACEUTICAL CO., INC.
      • 11.1.9.1 Business overview
      • 11.1.9.2 Products offered
      • 11.1.9.3 Recent developments
        • 11.1.9.3.1 Product launches, enhancements, and approvals
        • 11.1.9.3.2 Deals
        • 11.1.9.3.3 Expansions
    • 11.1.10 CIPLA
      • 11.1.10.1 Business overview
      • 11.1.10.2 Products offered
      • 11.1.10.3 Recent developments
        • 11.1.10.3.1 Deals
    • 11.1.11 VIATRIS INC.
      • 11.1.11.1 Business overview
      • 11.1.11.2 Products offered
      • 11.1.11.3 Recent developments
        • 11.1.11.3.1 Product launches & approvals
        • 11.1.11.3.2 Deals
        • 11.1.11.3.3 Other developments
    • 11.1.12 ORGANON GROUP OF COMPANIES
      • 11.1.12.1 Business overview
      • 11.1.12.2 Products offered
      • 11.1.12.3 Recent developments
        • 11.1.12.3.1 Product approvals
        • 11.1.12.3.2 Deals
    • 11.1.13 PFIZER, INC.
      • 11.1.13.1 Business overview
      • 11.1.13.2 Products offered
      • 11.1.13.3 Recent developments
        • 11.1.13.3.1 Product approvals
        • 11.1.13.3.2 Deals
    • 11.1.14 CRESCITA THERAPEUTICS INC.
      • 11.1.14.1 Business overview
      • 11.1.14.2 Products offered
      • 11.1.14.3 Recent developments
        • 11.1.14.3.1 Deals
        • 11.1.14.3.2 Other developments
    • 11.1.15 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
      • 11.1.15.1 Business overview
      • 11.1.15.2 Products offered
      • 11.1.15.3 Recent developments
        • 11.1.15.3.1 Deals
        • 11.1.15.3.2 Expansions
    • 11.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD.
      • 11.1.16.1 Business overview
      • 11.1.16.2 Products offered
      • 11.1.16.3 Recent developments
        • 11.1.16.3.1 Deals
    • 11.1.17 SOLVENTUM
      • 11.1.17.1 Business overview
      • 11.1.17.2 Products offered
      • 11.1.17.3 Recent developments
        • 11.1.17.3.1 Deals
    • 11.1.18 LUYE PHARMA GROUP
      • 11.1.18.1 Business overview
      • 11.1.18.2 Products offered
      • 11.1.18.3 Recent developments
        • 11.1.18.3.1 Product approvals
        • 11.1.18.3.2 Deals
    • 11.1.19 LEAD CHEMICAL CO., LTD.
      • 11.1.19.1 Business overview
      • 11.1.19.2 Products offered
    • 11.1.20 PURDUE PHARMA L.P.
      • 11.1.20.1 Business overview
      • 11.1.20.2 Products offered
    • 11.1.21 LAVIPHARM
      • 11.1.21.1 Business overview
      • 11.1.21.2 Products offered
  • 11.2 OTHER PLAYERS
    • 11.2.1 CMP PHARMA, INC.
    • 11.2.2 ENCORE DERMATOLOGY, INC.
    • 11.2.3 RUSAN PHARMA LTD.
    • 11.2.4 ADHEXPHARMA

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 RELATED REPORTS
  • 12.4 AUTHOR DETAILS